 Nathan Rabinovitch
Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 27 | 2020 | 2051 | 4.060 |
Why?
| | Leukotriene E4 | 12 | 2018 | 27 | 3.190 |
Why?
| | Air Pollutants | 8 | 2020 | 244 | 1.990 |
Why?
| | Particulate Matter | 6 | 2020 | 185 | 1.880 |
Why?
| | Tobacco Smoke Pollution | 6 | 2020 | 217 | 1.790 |
Why?
| | Environmental Exposure | 8 | 2020 | 377 | 1.730 |
Why?
| | Environmental Monitoring | 6 | 2016 | 254 | 1.240 |
Why?
| | Air Pollution | 4 | 2020 | 170 | 1.050 |
Why?
| | Anti-Asthmatic Agents | 6 | 2018 | 350 | 1.050 |
Why?
| | Forced Expiratory Volume | 6 | 2015 | 476 | 1.000 |
Why?
| | Leukotriene Antagonists | 4 | 2013 | 41 | 0.950 |
Why?
| | Airway Obstruction | 2 | 2022 | 168 | 0.940 |
Why?
| | Acetates | 5 | 2014 | 95 | 0.920 |
Why?
| | Quinolines | 5 | 2014 | 129 | 0.890 |
Why?
| | Endotoxins | 3 | 2015 | 205 | 0.820 |
Why?
| | Albuterol | 6 | 2016 | 103 | 0.810 |
Why?
| | Cannabis | 2 | 2019 | 383 | 0.800 |
Why?
| | Receptors, Leukotriene | 2 | 2020 | 13 | 0.800 |
Why?
| | Antigens, Plant | 2 | 2018 | 47 | 0.740 |
Why?
| | Air Pollution, Indoor | 3 | 2013 | 108 | 0.710 |
Why?
| | Nitric Oxide | 3 | 2015 | 827 | 0.660 |
Why?
| | Models, Statistical | 3 | 2013 | 602 | 0.650 |
Why?
| | Rhinitis, Allergic, Seasonal | 2 | 2017 | 32 | 0.620 |
Why?
| | Asthma, Exercise-Induced | 1 | 2018 | 7 | 0.620 |
Why?
| | Child | 23 | 2023 | 18407 | 0.620 |
Why?
| | Dermatitis, Atopic | 2 | 2023 | 310 | 0.610 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 5 | 0.610 |
Why?
| | Vehicle Emissions | 1 | 2018 | 48 | 0.590 |
Why?
| | Allergens | 2 | 2018 | 417 | 0.590 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2389 | 0.580 |
Why?
| | Angioedema | 1 | 2017 | 16 | 0.570 |
Why?
| | Biomarkers | 8 | 2018 | 3419 | 0.560 |
Why?
| | Regression Analysis | 3 | 2018 | 948 | 0.550 |
Why?
| | DNA Methylation | 1 | 2020 | 496 | 0.530 |
Why?
| | Hypersensitivity | 1 | 2019 | 256 | 0.520 |
Why?
| | Anaphylaxis | 1 | 2018 | 148 | 0.510 |
Why?
| | Face | 1 | 2017 | 168 | 0.510 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 928 | 0.490 |
Why?
| | Marijuana Smoking | 1 | 2018 | 223 | 0.470 |
Why?
| | Bronchodilator Agents | 2 | 2013 | 243 | 0.460 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 254 | 0.450 |
Why?
| | Lung | 4 | 2022 | 3595 | 0.450 |
Why?
| | Arachis | 1 | 2015 | 147 | 0.440 |
Why?
| | Humans | 37 | 2023 | 115038 | 0.420 |
Why?
| | Adrenergic beta-Agonists | 1 | 2013 | 128 | 0.420 |
Why?
| | Peanut Hypersensitivity | 1 | 2015 | 199 | 0.390 |
Why?
| | Fungi | 1 | 2012 | 124 | 0.380 |
Why?
| | Risk | 4 | 2018 | 815 | 0.380 |
Why?
| | Cyclopropanes | 5 | 2014 | 81 | 0.370 |
Why?
| | Sulfides | 5 | 2014 | 94 | 0.360 |
Why?
| | Diet | 1 | 2015 | 1076 | 0.310 |
Why?
| | Adolescent | 12 | 2018 | 17862 | 0.280 |
Why?
| | Personal Space | 1 | 2005 | 2 | 0.260 |
Why?
| | Cotinine | 2 | 2020 | 67 | 0.240 |
Why?
| | Public Health | 1 | 2008 | 435 | 0.230 |
Why?
| | Receptors, IgG | 1 | 2004 | 67 | 0.230 |
Why?
| | Male | 16 | 2018 | 55729 | 0.220 |
Why?
| | Androstadienes | 2 | 2014 | 97 | 0.220 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 144 | 0.220 |
Why?
| | Pyrin | 1 | 2023 | 2 | 0.220 |
Why?
| | Models, Theoretical | 1 | 2006 | 517 | 0.200 |
Why?
| | Monte Carlo Method | 2 | 2013 | 137 | 0.200 |
Why?
| | Inhalation Exposure | 2 | 2013 | 97 | 0.200 |
Why?
| | Antigens, CD | 1 | 2004 | 441 | 0.190 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 523 | 0.190 |
Why?
| | Smoking | 1 | 2008 | 1392 | 0.190 |
Why?
| | Female | 15 | 2017 | 59610 | 0.190 |
Why?
| | Particle Size | 3 | 2007 | 317 | 0.190 |
Why?
| | Dyspnea | 1 | 2022 | 218 | 0.180 |
Why?
| | Health Status | 1 | 2006 | 722 | 0.180 |
Why?
| | Models, Biological | 1 | 2007 | 1636 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2011 | 2551 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2023 | 617 | 0.170 |
Why?
| | Exercise Test | 1 | 2022 | 545 | 0.170 |
Why?
| | B-Lymphocytes | 1 | 2004 | 772 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 192 | 0.160 |
Why?
| | Soy Foods | 1 | 2018 | 3 | 0.160 |
Why?
| | Diet Therapy | 1 | 2018 | 36 | 0.150 |
Why?
| | Skin Tests | 1 | 2018 | 123 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2012 | 316 | 0.150 |
Why?
| | Causality | 1 | 2018 | 105 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 496 | 0.150 |
Why?
| | Immunity, Innate | 1 | 2023 | 723 | 0.140 |
Why?
| | Pollen | 1 | 2017 | 24 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2017 | 20 | 0.140 |
Why?
| | Epinephrine | 1 | 2018 | 167 | 0.140 |
Why?
| | Pruritus | 1 | 2017 | 60 | 0.140 |
Why?
| | Trees | 1 | 2017 | 62 | 0.140 |
Why?
| | Fluticasone | 2 | 2014 | 87 | 0.140 |
Why?
| | Computer Systems | 1 | 2016 | 46 | 0.140 |
Why?
| | Geographic Information Systems | 1 | 2016 | 37 | 0.140 |
Why?
| | Cities | 1 | 2016 | 81 | 0.140 |
Why?
| | Steroids | 1 | 2017 | 147 | 0.140 |
Why?
| | Disease Progression | 2 | 2018 | 2389 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2011 | 1812 | 0.130 |
Why?
| | Administration, Oral | 1 | 2018 | 730 | 0.130 |
Why?
| | User-Computer Interface | 1 | 2016 | 143 | 0.130 |
Why?
| | Immunization | 1 | 2018 | 400 | 0.130 |
Why?
| | Cross-Over Studies | 2 | 2014 | 441 | 0.120 |
Why?
| | Colorado | 2 | 2016 | 4089 | 0.120 |
Why?
| | Nitrogen Dioxide | 1 | 2013 | 20 | 0.110 |
Why?
| | Salmeterol Xinafoate | 1 | 2013 | 41 | 0.110 |
Why?
| | Eczema | 1 | 2014 | 82 | 0.110 |
Why?
| | Leukocyte Count | 1 | 2013 | 292 | 0.110 |
Why?
| | Vital Capacity | 1 | 2013 | 257 | 0.110 |
Why?
| | Mutation | 1 | 2023 | 3350 | 0.100 |
Why?
| | Pilot Projects | 1 | 2016 | 1375 | 0.100 |
Why?
| | Linear Models | 2 | 2011 | 776 | 0.100 |
Why?
| | Eosinophils | 1 | 2013 | 281 | 0.100 |
Why?
| | Nicotine | 1 | 2013 | 266 | 0.090 |
Why?
| | Nebulizers and Vaporizers | 1 | 2011 | 78 | 0.090 |
Why?
| | Markov Chains | 1 | 2011 | 114 | 0.090 |
Why?
| | Drug Utilization | 1 | 2011 | 167 | 0.090 |
Why?
| | Urban Health | 2 | 2013 | 73 | 0.090 |
Why?
| | Cluster Analysis | 1 | 2011 | 458 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2011 | 641 | 0.080 |
Why?
| | Computer Simulation | 1 | 2013 | 880 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 192 | 0.080 |
Why?
| | Immunoglobulin E | 1 | 2010 | 323 | 0.080 |
Why?
| | Age of Onset | 1 | 2010 | 449 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 499 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2341 | 0.080 |
Why?
| | Breath Tests | 1 | 2008 | 83 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 474 | 0.070 |
Why?
| | Software | 1 | 2011 | 537 | 0.070 |
Why?
| | Sulfates | 1 | 2007 | 43 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2009 | 413 | 0.070 |
Why?
| | Maximum Allowable Concentration | 1 | 2006 | 14 | 0.070 |
Why?
| | Epidemiological Monitoring | 1 | 2006 | 48 | 0.060 |
Why?
| | Iron | 1 | 2007 | 234 | 0.060 |
Why?
| | Calibration | 1 | 2006 | 126 | 0.060 |
Why?
| | Meteorological Concepts | 1 | 2004 | 5 | 0.060 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2004 | 23 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 23 | 0.060 |
Why?
| | Tetanus | 1 | 2004 | 25 | 0.060 |
Why?
| | Cold Temperature | 1 | 2004 | 129 | 0.060 |
Why?
| | Budesonide | 1 | 2004 | 87 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 88 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 114 | 0.060 |
Why?
| | Pituitary-Adrenal System | 1 | 2004 | 130 | 0.050 |
Why?
| | School Health Services | 1 | 2006 | 206 | 0.050 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2004 | 164 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 1721 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 10498 | 0.050 |
Why?
| | Research Design | 1 | 2008 | 930 | 0.050 |
Why?
| | Schools | 1 | 2005 | 400 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2013 | 4420 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2004 | 791 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2007 | 1019 | 0.050 |
Why?
| | Chronic Disease | 1 | 2006 | 1591 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2004 | 1084 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 4631 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 1811 | 0.040 |
Why?
| | Risk Assessment | 1 | 2006 | 2976 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2010 | 9122 | 0.030 |
Why?
| | Cohort Studies | 1 | 2006 | 4904 | 0.030 |
Why?
| | United States | 1 | 2011 | 12224 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 12 | 0.030 |
Why?
| | Baltimore | 1 | 2013 | 43 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 287 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 184 | 0.030 |
Why?
| | Child, Preschool | 3 | 2013 | 9093 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 8642 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1715 | 0.020 |
Why?
| | Aerosols | 1 | 2004 | 151 | 0.010 |
Why?
| | Prospective Studies | 1 | 2013 | 6232 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2799 | 0.010 |
Why?
| | Patient Compliance | 1 | 2004 | 524 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2004 | 1664 | 0.010 |
Why?
| | Middle Aged | 1 | 2009 | 26826 | 0.010 |
Why?
| | Adult | 1 | 2009 | 30654 | 0.000 |
Why?
|
|
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|